SG11201407216YA - Benzo[1,3]dioxine derivatives and their use as lpar5 antagonists - Google Patents
Benzo[1,3]dioxine derivatives and their use as lpar5 antagonistsInfo
- Publication number
- SG11201407216YA SG11201407216YA SG11201407216YA SG11201407216YA SG11201407216YA SG 11201407216Y A SG11201407216Y A SG 11201407216YA SG 11201407216Y A SG11201407216Y A SG 11201407216YA SG 11201407216Y A SG11201407216Y A SG 11201407216YA SG 11201407216Y A SG11201407216Y A SG 11201407216YA
- Authority
- SG
- Singapore
- Prior art keywords
- sanofi
- frankfurt
- main
- international
- lpar5
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title abstract 3
- TWSIYGATPWEKBK-UHFFFAOYSA-N 4h-1,3-benzodioxine Chemical class C1=CC=C2OCOCC2=C1 TWSIYGATPWEKBK-UHFFFAOYSA-N 0.000 title 1
- 101001038037 Homo sapiens Lysophosphatidic acid receptor 5 Proteins 0.000 abstract 7
- 150000001875 compounds Chemical class 0.000 abstract 5
- 102100040404 Lysophosphatidic acid receptor 5 Human genes 0.000 abstract 3
- 210000003630 histaminocyte Anatomy 0.000 abstract 2
- 210000000274 microglia Anatomy 0.000 abstract 2
- HGUFODBRKLSHSI-UHFFFAOYSA-N 2,3,7,8-tetrachloro-dibenzo-p-dioxin Chemical class O1C2=CC(Cl)=C(Cl)C=C2OC2=C1C=C(Cl)C(Cl)=C2 HGUFODBRKLSHSI-UHFFFAOYSA-N 0.000 abstract 1
- OXSYGCRLQCGSAQ-UHFFFAOYSA-N CC1CCC2N(C1)CC3C4(O)CC5C(CCC6C(O)C(O)CCC56C)C4(O)CC(O)C3(O)C2(C)O Chemical compound CC1CCC2N(C1)CC3C4(O)CC5C(CCC6C(O)C(O)CCC56C)C4(O)CC(O)C3(O)C2(C)O OXSYGCRLQCGSAQ-UHFFFAOYSA-N 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000001435 Thromboembolism Diseases 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 210000001772 blood platelet Anatomy 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
- C07D319/08—1,3-Dioxanes; Hydrogenated 1,3-dioxanes condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12305553 | 2012-05-18 | ||
| PCT/EP2013/060172 WO2013171318A1 (en) | 2012-05-18 | 2013-05-16 | Benzo[1,3]dioxine derivatives and their use as lpar5 antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201407216YA true SG11201407216YA (en) | 2014-12-30 |
Family
ID=48468297
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201407216YA SG11201407216YA (en) | 2012-05-18 | 2013-05-16 | Benzo[1,3]dioxine derivatives and their use as lpar5 antagonists |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9221784B2 (https=) |
| EP (1) | EP2850070B1 (https=) |
| JP (1) | JP6238970B2 (https=) |
| KR (1) | KR20150016304A (https=) |
| CN (1) | CN104302633B (https=) |
| AU (1) | AU2013261719B2 (https=) |
| BR (1) | BR112014028189A2 (https=) |
| CA (1) | CA2871545A1 (https=) |
| ES (1) | ES2649438T3 (https=) |
| IL (1) | IL235219A (https=) |
| MX (1) | MX354521B (https=) |
| PL (1) | PL2850070T3 (https=) |
| RU (1) | RU2647727C2 (https=) |
| SG (1) | SG11201407216YA (https=) |
| SI (1) | SI2850070T1 (https=) |
| WO (1) | WO2013171318A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3106692A1 (en) * | 2017-07-19 | 2019-01-24 | Aazeintx Inc. | Method to abate acute airway hypersensitivity and asthma attacks |
| KR20250140741A (ko) | 2024-03-19 | 2025-09-26 | 경북대학교 산학협력단 | 알룰로스를 포함하는 혈전 예방 또는 개선용 조성물 및 이의 이용 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4056540A (en) | 1974-01-01 | 1977-11-01 | Bristol-Myers Company | 4-Phenyl-1,3-benzodioxans |
| US4056450A (en) | 1975-06-30 | 1977-11-01 | M & T Chemicals Inc. | Continuous detinning system |
| FR2424914A2 (fr) * | 1978-05-03 | 1979-11-30 | Roussel Uclaf | Nouveaux derives de (1-3) benzodioxine, un procede pour leur preparation et leur application comme medicaments |
| SE7902817L (sv) * | 1978-05-03 | 1979-11-04 | Roussel Uclaf | Substituerade /4h/ 1,3-bensodioxin-2-karboxylsyraderivat, framstellning och anvendning derav sasom lekemedel samt farmaceutiska kompositioner innehallande dessa |
| GB8310407D0 (en) * | 1982-05-12 | 1983-05-25 | Ici Plc | 1 3 - dioxan -5- ylalkenoic acids |
| FR2704857B1 (fr) * | 1993-05-07 | 1995-06-23 | Adir | Nouvelles benzodioxines substituées, leur procédé de préparation et les compositions pharmaceutiques les contenant. |
| WO2004113274A2 (en) * | 2003-05-20 | 2004-12-29 | Bayer Pharmaceuticals Corporation | Diaryl ureas with kinase inhibiting activity |
| CN101124226A (zh) * | 2004-05-07 | 2008-02-13 | 记忆药物公司 | 1h-吲唑、苯并噻唑、1,2-苯并异噁唑、1,2-苯并异噻唑和色酮以及它们的制备和用途 |
| WO2010042600A2 (en) * | 2008-10-08 | 2010-04-15 | The Uab Research Foundation | Photo-activatable therapeutic agents and methods of using |
-
2013
- 2013-05-16 CN CN201380025938.2A patent/CN104302633B/zh not_active Expired - Fee Related
- 2013-05-16 RU RU2014151240A patent/RU2647727C2/ru not_active IP Right Cessation
- 2013-05-16 SI SI201330853T patent/SI2850070T1/en unknown
- 2013-05-16 JP JP2015512073A patent/JP6238970B2/ja not_active Expired - Fee Related
- 2013-05-16 ES ES13723767.3T patent/ES2649438T3/es active Active
- 2013-05-16 MX MX2014014012A patent/MX354521B/es active IP Right Grant
- 2013-05-16 EP EP13723767.3A patent/EP2850070B1/en not_active Not-in-force
- 2013-05-16 KR KR20147033844A patent/KR20150016304A/ko not_active Withdrawn
- 2013-05-16 PL PL13723767T patent/PL2850070T3/pl unknown
- 2013-05-16 SG SG11201407216YA patent/SG11201407216YA/en unknown
- 2013-05-16 US US14/401,041 patent/US9221784B2/en not_active Expired - Fee Related
- 2013-05-16 AU AU2013261719A patent/AU2013261719B2/en not_active Ceased
- 2013-05-16 WO PCT/EP2013/060172 patent/WO2013171318A1/en not_active Ceased
- 2013-05-16 CA CA 2871545 patent/CA2871545A1/en not_active Abandoned
- 2013-05-16 BR BR112014028189A patent/BR112014028189A2/pt not_active Application Discontinuation
-
2014
- 2014-10-20 IL IL235219A patent/IL235219A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013171318A1 (en) | 2013-11-21 |
| US20150111889A1 (en) | 2015-04-23 |
| CA2871545A1 (en) | 2013-11-21 |
| BR112014028189A2 (pt) | 2017-06-27 |
| AU2013261719A1 (en) | 2014-12-18 |
| SI2850070T1 (en) | 2018-01-31 |
| PL2850070T3 (pl) | 2018-01-31 |
| JP2015517515A (ja) | 2015-06-22 |
| RU2014151240A (ru) | 2016-07-10 |
| ES2649438T3 (es) | 2018-01-12 |
| AU2013261719B2 (en) | 2017-07-27 |
| CN104302633A (zh) | 2015-01-21 |
| CN104302633B (zh) | 2016-09-07 |
| MX354521B (es) | 2018-03-08 |
| RU2647727C2 (ru) | 2018-03-19 |
| KR20150016304A (ko) | 2015-02-11 |
| JP6238970B2 (ja) | 2017-11-29 |
| MX2014014012A (es) | 2015-02-12 |
| IL235219A (en) | 2017-03-30 |
| EP2850070A1 (en) | 2015-03-25 |
| US9221784B2 (en) | 2015-12-29 |
| EP2850070B1 (en) | 2017-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201804577RA (en) | Fgf21 variants | |
| SG11201408094YA (en) | Neprilysin inhibitors | |
| SG11201403402VA (en) | Compounds | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201903908PA (en) | Novel substituted n-(3-fluoropropyl)-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof | |
| SG11201808878UA (en) | Heterocyclic compounds as ret kinase inhibitors | |
| SG11201907604UA (en) | Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan | |
| SG11201808106YA (en) | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation | |
| SG11201407534PA (en) | New diazaspirocycloalkane and azaspirocycloalkane | |
| SG11201407228PA (en) | N-aryltriazole compounds as lpar antagonists | |
| SG11201809126RA (en) | Aromatic sulfonamide derivatives | |
| SG11201407860PA (en) | Exendin-4 peptide analogues | |
| SG11201407210SA (en) | Pyrazole derivatives and their use as lpar5 antagonists | |
| SG11201408123SA (en) | Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical compositions thereof | |
| SG11201407961WA (en) | Risperidone or paliperidone implant formulation | |
| SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
| SG11201806424TA (en) | Therapeutic compounds | |
| SG11201407536UA (en) | Topical pharmaceutical compositions comprising terbinafine and urea | |
| SG11201809470RA (en) | Substituted indazoles useful for treatment and prevention of allergic and/or inflammatory diseases in animals | |
| SG11201407037UA (en) | Catechol o-methyltransferase activity inhibiting compounds | |
| SG11201909735YA (en) | Therapeutic compounds and compositions, and methods of use thereof | |
| SG11201805368YA (en) | Anthelmintic depsipeptide compounds | |
| SG11201903195YA (en) | Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders | |
| SG11201407575PA (en) | 5-amino[1,4]thiazines as bace 1 inhibitors | |
| SG11201900021PA (en) | Methods and compositions for the treatment of cancer |